

ASX Release

Anatara Releases 4C

Key points:

- **Revenue of \$2.283M for the quarter**
- **Positive quarter cash flow**
- **Cash increases to \$13.7M**

BRISBANE, 22nd July 2016: Anatara Lifesciences (ASX:ANR) today released its quarterly Appendix 4C – 4th Quarter Report.

Chairman & CEO, Dr Mel Bridges said, “We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch,” Dr Bridges added.

Anatara’s DetachTM technology has potential to play a part as an alternative to traditional antibiotics to treat gastrointestinal diseases in farm (production) animals and humans.

For more information please contact:

General inquiries Mel Bridges Chairman, Anatara Lifesciences +61 (0) 413 051 600 mbridges@anataralifesciences.com	Media inquiries Jane Lowe ir department +61 (0) 411117774 jane.lowe@irdepartment.com.au
--	---

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product DetachTM is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Appendix 4C – 4th Quarter

Quarterly Report for Entities Admitted on the Basis of Commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of Entity:

Anatara Lifesciences Ltd (ASX: ANR)

ABN:

41 145 239 872

Quarter Ended ('Current Quarter')

30 June 2016

Consolidated Statement of Cash Flows

<u>Cash Flows Related to Operating Activities</u>		Current Quarter \$A'000	Year-to-Date (12 months) \$A'000
1.1	Receipts from customers	2,283	2,283
1.2	Payments for:		
	(a) staff costs (including R&D staffing costs)	(275)	(1,023)
	(b) advertising/marketing/investor relations	-	-
	(c) research and development (excluding R&D staffing costs)	(238)	(829)
	(d) leased assets	-	-
	(e) other working capital	(315)	(1,134)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	66	267
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes refund	-	-
1.7	R&D Tax Concession refund	-	165
Net Operating Cash Flows		(1,521)	(271)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments

		Current Quarter \$A'000	Year-to-Date (12 months) \$A'000
1.8	Net Operating Cash Flows (carried forward)	(1,521)	(271)
<u>Cash Flows Related to Investing Activities</u>			
1.9	Payment for acquisition of:		
	(a) businesses (item)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
Net Investing Cash Flows		-	-
1.14	Total Operating and Investing Cash Flows	(1,521)	(271)
<u>Cash Flows Related to Financing Activities</u>			
1.15	Proceeds from issues of shares, options, etc.	-	8,616
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (Capital Raising Costs)	-	(155)
Net Financing Cash Flows		-	8,461
Net Increase / (Decrease) in Cash Held		(1,521)	8,190
1.21	Cash at beginning of quarter/year to date	12,166	5,497
1.22	Exchange rate adjustments to item 1.21	-	-
1.23	Cash at End of Quarter	13,687	13,687

+ See chapter 19 for defined terms.

Payments to Directors of the Entity and Associates of the Directors

Payments to Related Entities of the Entity and Associates of the Related Entities

	Current Quarter SA'000
1.24 Aggregate amount of payments to the parties included in item 1.2	163
1.25 Aggregate amount of loans to the parties included in item 1.11	-
1.26 Explanation necessary for an understanding of the transactions	
Item 1.24 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).	

Non-Cash Financing and Investing Activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing Facilities Available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount Available SA'000	Amount Used SA'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments

Reconciliation of Cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current Quarter SA'000	Previous Quarter SA'000
4.1 Cash on hand and at bank	1,387	866
4.2 Deposits at call	12,300	11,300
4.3 Bank overdraft	-	-
4.4 Other - Bank Guarantee / Trust	-	-
Total: Cash at End of Quarter (item 1.23)	13,687	12,166

Acquisitions and Disposals of Business Entities


	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign Here:

Print Name:


DR. MEL BRIDGES

Date:

22 / 7 / 2016

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.